New prognostic scoring system for primary myelofibrosis based on a study of the International working group for myelofibrosis research and treatment

Francisco Cervantes, Brigitte Dupriez, Arturo Pereira, Francesco Passamonti, John T. Reilly, Enrica Morra, Alessandro M. Vannucchi, Ruben A. Mesa, Jean Loup Demory, Giovanni Barosi, Elisa Rumi, Ayalew Tefferi

Research output: Contribution to journalArticle

Abstract

Therapeutic decision-making in primary myelofibrosis (PMF) is becoming more challenging because of the increasing use of allogeneic stem cell transplantation and new investigational drugs. To enhance this process by developing a highly discriminative prognostic system, 1054 patients consecutively diagnosed with PMF at 7 centers were studied. Overall median survival was 69 months (95% confidence interval [CI]: 61-76). Multivari- ate analysis of parameters obtained at disease diagnosis identified age greater than 65 years, presence of constitutional symptoms, hemoglobin level less than 10 g/dL, leukocyte count greater than 25 × 10 9/L, and circulating blast cells 1% or greater as predictors of shortened survival. Based on the presence of 0 (low risk), 1 (intermediate risk-1), 2 (intermediate risk-2) or greater than or equal to 3 (high risk) of these variables, 4 risk groups with no overlapping in their survival curves were delineated; respective median survivals were 135, 95, 48, and 27 months (P

Original languageEnglish
Pages (from-to)2895-2901
Number of pages7
JournalBlood
Volume113
Issue number13
DOIs
Publication statusPublished - Mar 26 2009

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Fingerprint Dive into the research topics of 'New prognostic scoring system for primary myelofibrosis based on a study of the International working group for myelofibrosis research and treatment'. Together they form a unique fingerprint.

Cite this